TACR1 and central nervous system cancer: Notably, Muñoz and Rosso (2010) were the first to demonstrate its broad‐spectrum antitumor activity, showing that aprepitant induces dose‐dependent growth inhibition and apoptosis across multiple human cancer cell lines, including glioma, thereby emphasizing its antitumor effects mediated through NK‐1R blockade [8].